Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Advancements in cancer biology in developed region
3.2.1.2 Expanding portfolio of precision medicine drugs
3.2.1.3 Increasing adoption of gene therapy
3.2.2 Industry pitfalls & challenges
3.2.2.1 High cost of precision medicine
3.2.2.2 Stringent regulatory norms
3.3 Growth potential analysis
3.4 Pipeline analysis
3.5 Future market trends
3.6 Regulatory landscape
3.7 Porter's analysis
3.8 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Application, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 Diagnostics
5.2.1 Genetic tests
5.2.2 Biomarker based tests
5.2.3 Esoteric tests
5.2.4 Other tests
5.3 Therapeutics
5.3.1 Inhibitor drugs
5.3.2 Monoclonal antibodies
5.3.3 Cell & gene therapy
5.3.4 Antiviral & anti-retroviral drugs
5.3.5 Other therapeutics
Chapter 6 Market Estimates and Forecast, By Indication, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 Oncology
6.3 CNS disorders
6.4 Immunology
6.5 Respiratory diseases
6.6 Genetic disorders
6.7 Skin diseases
6.8 Other indications
Chapter 7 Market Estimates and Forecast, By Technology, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 Genomics
7.3 Bioinformatics
7.4 Big data analytics
7.5 Biomarker detection
7.6 High throughput screening
7.7 Other technologies
Chapter 8 Market Estimates and Forecast, By End-user, 2021 – 2032 ($ Mn)
8.1 Key trends
8.2 Hospitals
8.3 Diagnostic laboratories
8.4 Other end-users
Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
9.1 Key trends
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Spain
9.3.5 Italy
9.3.6 Netherlands
9.3.7 Rest of Europe
9.4 Asia Pacific
9.4.1 China
9.4.2 Japan
9.4.3 India
9.4.4 Australia
9.4.5 South Korea
9.4.6 Rest of Asia Pacific
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Rest of Latin America
9.6 Middle East and Africa
9.6.1 South Africa
9.6.2 Saudi Arabia
9.6.3 UAE
9.6.4 Rest of Middle East and Africa
Chapter 10 Company Profiles
10.1 Abbott Laboratories, Inc.
10.2 Abbvie, Inc.
10.3 AstraZeneca plc
10.4 bioMerieux SA
10.5 Bristol-Myers Squibb Company
10.6 Cepheid (Danaher Corporation)
10.7 Eli Lilly & Company
10.8 F. Hoffmann-La Roche
10.9 GlaxoSmithKline plc
10.10 Laboratory Corporation of America Holdings (Covance Inc.)
10.11 Myriad Genetics, Inc.
10.12 Novartis AG
10.13 Pfizer, Inc.
10.14 QIAGEN N.V.
10.15 Quest Diagnostics
10.16 Takeda Pharmaceutical Company Limited
10.17 Thermo Fisher Scientific Inc.
10.18 Vyant Bio, Inc. (Cancer Genetics, Inc.)
